Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Shareholder Meeting (November 2025)
10 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 18, 2025
Slide 1: Life-changing science: AGM presentation November 2025
For personal use only Life-changing science AGM presentation November 2025
Slide 2: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of PYC Therapeutics about the future, you are urged to view all forward looking statements contained in this For personal use only Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only
Slide 3: Agenda
Agenda For personal use only • An introduction to PYC • 2025 highlights • What PYC is looking forward to in 2026 • Q&A PYC THERAPEUTICS 3
Slide 4: An introduction to PYC Therapeutics
An introduction to PYC Therapeutics • PYC is a drug discovery and development company focused on creating life-changing For personal use only new therapies for patients who have genetic diseases and no treatment options available today • PYC’s strategy is to use RNA therapeutics to increase gene exp
Slide 5: PYC has built a pipeline of drug candidates with potential to become standard of care
PYC has built a pipeline of drug candidates with the potential to become the standard of care in areas of major unmet need Historical progress Progress expected in 20251 For personal use only Program Pre-clinical Clinical Prevalence2 VP-0013 Retinitis Pigmentosa Type 11 1 in 100,000 PYC-001 Autosoma
Slide 6: For personal use only
For personal use only PYC THERAPEUTICS
Slide 7: 2025 highlights
2025 highlights For personal use only • Progression of the Polycystic Kidney Disease (PKD) program into human trials1 • Pre-clinical data in Phelan-McDermid Syndrome2 • Phase 1/2 data in the Retinitis Pigmentosa type 11 trial3 1. See ASX announcement of 10 April 2025 2. See ASX announcement of 13 Oc
Slide 8: Novartis CEO on US$12 billion Avidity Biosciences acquisition
For personal use only “In our view, the phase-appropriate risk was reasonable given the data that we’ve seen” Narasimhan said “The deal could have been ‘twice as big’ if the Swiss giant had waited for a highly anticipated Phase 3 readout” Novartis CEO Vas Narasimhan on US$12 billion Avidity Bioscien
Slide 9: 2026/27 Forward view
2026/27 Forward view1 For personal use only Program 2026 milestones 2027 milestones Polycystic Kidney Disease (PKD) • Safety/tolerability data in PKD patients • Safety/tolerability data in PKD patients • Efficacy data (3-6 months) from multiple • Efficacy data (6-12+ months) from dose studies multip
Slide 10: Q&A
For personal use only Life-changing science Q&A November 2025
PYC Therapeutics — Shareholder Meeting (November 2025) on 6ix